Gardiquimod™ Gardiquimod™ is a imidazoquinoline compound developed and manufactured by InvivoGen. Similarly to Imiquimod, Gardiquimod™ induces the activation of NF-κB in HEK293 cells expressing human or mouse TLR7. However Gardiquimod™ is 10 times more active as a concentration of 0.1 µg/ml is sufficient to detect NF-κB activation whereas Imiquimod requires a concentration of 1 µg/ml. At high concentrations (3 µg/ml), Gardiquimod™ slightly activates TLR8 and no other TLRs suggesting that Gardiquimod™ is specific of TLR7 and TLR8. Specificity: human/mouse TLR7 agonist Working concentration: 1 - 10 µg/ml Endotoxin level: EndoFit™ (<0.001 EU/μg) Solubility: 1 mg/ml in water